Studies have shown that metallothionein (MT) is overexpressed in some @entity1 @entity150 and that overexpression can predict treatment response to neoadjuvant @entity900 , @entity1499 , and @entity5713 chemotherapy. In the present study the UROtsa cell line, a model of normal @entity1 urothelium, was used to determine the expression of the @entity1 @entity69240 genes and MT protein following exposure to @entity10278 or @entity15827 at lethal and sublethal levels. Acute exposure was modeled by treating confluent cultures with 100 microM @entity15827 or 53.4 microM @entity10278 for 4 h followed by a 48-h recovery period. Extended exposure was modeled by treating confluent cells with 1, 4, and 8 microM @entity13303 or 1, 5, and 9 microM @entity3280 for 16 d, with the highest concentrations producing cell lethality. The expression of MT mRNAs and protein were determined by reverse-transcription polymerase chain reaction (RT-PCR) and immunoblot analysis. Cell viability was determined by the @entity98 assay. It was shown that acute exposure to either @entity13303 or @entity3280 increased the levels of mRNAs for the @entity21035 , @entity40174 , and @entity13498 genes, whereas extended exposure only increased these mRNAs following exposure to @entity3280 . It was shown that both acute and extended exposure to either @entity13303 or @entity3280 increased the levels of MT protein, reaching a maximal value of 8 ng MT protein/microg total protein for acute exposure to @entity3280 . This is in contrast to previous studies using cultured @entity1 proximal tubule cells, where similar extended treatment with @entity3280 resulted in over 20-fold higher MT protein levels. These studies demonstrate that @entity1 urothelial cells accumulate only modest amounts of MT protein when exposed to either @entity3280 or @entity69241 for a 16-d time period.

Metallothionein isoform 1 and 2 gene expression in a @entity1 urothelial cell line (UROtsa) exposed to XXXX and @entity15827 .

@entity1 :: ('9606', 'Species') :: ['human'] @entity21035 :: ('4493', 'Gene') :: ['MT-1E'] @entity69241 :: ('MESH:C021591', 'Chemical') :: ['As(2+)'] @entity40174 :: ('4501', 'Gene') :: ['MT-1X'] @entity3280 :: ('CHEBI:48775', 'Chemical') :: ['Cd(2+)'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity15827 :: ('CHEBI:29678', 'Chemical') :: ['NaAsO(2)'] @entity98 :: ('CHEBI:53233', 'Chemical') :: ['MTT'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancers'] @entity13498 :: ('4502', 'Gene') :: ['MT-2A'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity69240 :: ('4493;4502', 'Gene') :: ['MT-1 and MT-2'] @entity10278 :: ('MESH:D019256', 'Chemical') :: ['CdCl(2)'] @entity13303 :: ('CHEBI:35836', 'Chemical') :: ['As(3+)'] @entity5713 :: ('MESH:D014747', 'Chemical') :: ['vinblastine']
@entity10278 :: (MESH:D019256,Chemical) :: ['CdCl2']
